Article
Medical Laboratory Technology
Philip G. Drennan, Yann Thoma, Lucinda Barry, Johan Matthey, Sheila Sivam, Sebastiaan J. van Hal
Summary: The study demonstrates that using Bayesian forecasting with single postinfusion concentrations for assessing AUC(24) is feasible in routine practice, yielding similar exposure estimates to more intensive methods.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Pharmacology & Pharmacy
Jeremy Reverchon, Vianney Tuloup, Romain Garreau, Viviane Nave, Sabine Cohen, Philippe Reix, Stephane Durupt, Raphaele Nove-Josserand, Isabelle Durieu, Quitterie Reynaud, Laurent Bourguignon, Sandrine Charles, Sylvain Goutelle
Summary: The study on tobramycin MIPD in adult CF patients showed that MIPD was effective in changing prescribing practice, increasing tobramycin doses without causing renal function impairment.
Article
Microbiology
Antonin Praet, Laurent Bourguignon, Florence Vetele, Valentine Breant, Charlotte Genestet, Oana Dumitrescu, Anne Doleans-Jordheim, Philippe Reix, Sylvain Goutelle
Summary: This study developed nonparametric population pharmacokinetic (PK) models of tobramycin in children with CF for dosage design and model-guided therapeutic drug monitoring, with a recommended daily dose of 12.5 mg/kg optimizing efficacy and safety targets in most patients as validated through simulations.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Chemistry, Multidisciplinary
Chelsea R. Thorn, Cristiane de Souza Carvalho-Wodarz, Justus C. Horstmann, Claus-Michael Lehr, Clive A. Prestidge, Nicky Thomas
Summary: A biomimetic, nanostructured, lipid liquid crystal nanoparticle formulation has been discovered to significantly enhance the efficacy of tobramycin and eradicate Pseudomonas aeruginosa biofilm infections. This formulation improves antibiotic penetration across the biofilm barrier, leading to increased antibiotic concentration at the infection site. The nanoparticle strategy enables lower doses, reduced toxicity, and amplified anti-biofilm activity of the antibiotic.
Article
Pharmacology & Pharmacy
Zara Sheikh, Peta Bradbury, Tristan A. Reekie, Michele Pozzoli, Paul D. Robinson, Michael Kassiou, Paul M. Young, Hui Xin Ong, Daniela Traini
Summary: Current study investigated the potential interactions between the anti-inflammatory agent Ibuprofen and CF-approved inhaled antibiotics, revealing differential effects on the antibacterial and anti-inflammatory efficacy of the combinations. The study highlighted the importance of understanding drug-drug interactions and highlighted the inherent anti-inflammatory properties of the antibiotics used in CF treatment.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Respiratory System
Ramaa Puvvadi, Helga Mikkelsen, Lucy McCahon, Samantha Grogan, William Ditcham, David W. Reid, Iain Lamont, Stephen M. Stick, Barry Clements
Summary: This study found that adding Tris-CaEDTA to nebulised tobramycin could increase P. aeruginosa clearance and improve lung function in CF patients, although the differences were not statistically significant. The treatment was also shown to be safe and well-tolerated.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Pediatrics
Katherine B. Landmesser, Elizabeth B. Autry, Brian M. Gardner, Katherine A. Bosko, Aric Schadler, Robert J. Kuhn
Summary: The study found that both AUC(24) and C-max are relatively accurate predictors of tobramycin efficacy, while multiple daily dosing of IV tobramycin significantly increases the incidence of AKI and should be avoided in patients with CF.
PEDIATRIC PULMONOLOGY
(2021)
Article
Medical Laboratory Technology
Mehdi El Hassani, Daniel J. G. Thirion, Kevin Koloskoff, Elias Matouk, Chantale Simard, Isabelle Cloutier, Sylvie Pilote, Amelie Marsot
Summary: This study aimed to develop a height-based initial dosing nomogram and evaluate its performance in peak concentration (Cmax) precision relative to standard and fixed dosing. Height-based dosing resulted in significantly less variable-predicted Cmax values than the Cmax values observed in clinical practice and predicted Cmax values obtained from a fixed dose. An initial dosing nomogram was developed to help reduce pharmacokinetic variability in the observed Cmax, which would allow for better clinical outcomes in adult patients with cystic fibrosis.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Infectious Diseases
Tyler Miller, Cristina Pastuch, Lisa Garavaglia, Kelley Gannon, Anthony Parravani
Summary: This case report highlights the development of acute kidney injury in a cystic fibrosis patient with chronic kidney disease who was undergoing nebulized tobramycin inhalation treatment. Regular monitoring of drug serum levels and related function tests is essential in preventing permanent renal damage in patients receiving chronic nebulized therapy.
Article
Pediatrics
Tiffany E. Burrus, Hilary Vogt, Rebecca S. Pettit
Summary: The addition of a pharmacy technician/pharmacist team in conjunction with an integrated health-system specialty pharmacy (IHSSP) reduced the time from culture to TIS being received by CF patients. Patients who filled prescriptions at the IHSSP received their medication sooner compared to an external specialty pharmacy, highlighting the benefits of the integrated pharmacy model.
PEDIATRIC PULMONOLOGY
(2021)
Article
Respiratory System
Lotte C. C. Terpstra, Josje Altenburg, Inez Bronsveld, Martijn D. D. de Kruif, Yvonne Berk, Dominic Snijders, Wouter Rozemeijer, Harry G. M. Heijerman, Wim G. G. Boersma
Summary: In this study, long-term once daily use of tobramycin inhalation solution (TIS) was found to reduce exacerbation frequency and improve quality of life in bronchiectasis patients. This treatment modality was safe and may be a potential therapeutic strategy for patients with bronchiectasis suffering from a high burden of disease.
RESPIRATORY RESEARCH
(2022)
Article
Respiratory System
Angela Garinis, Malcolm Gleser, Alexis Johns, Erik Larsen, Jay Vachhani
Summary: The study revealed that a single course of IV tobramycin can cause ototoxic hearing loss in some CF patients, emphasizing the need for routine ototoxicity monitoring and management in this clinical population. CF patients are suitable for clinical trials examining ototherapeutics in single IV tobramycin treatment episodes.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Respiratory System
E. Emily Harruff, Jonathan Kil, Maria Gabriela Tupayachi Ortiz, Daniel Dorgan, Raksha Jain, Elizabeth A. Poth, Robert C. Fifer, Yun Jin M. Kim, Angela G. Shoup, Patrick A. Flume
Summary: Aminoglycosides, commonly used to treat infections in CF patients, are highly ototoxic. The study aimed to determine the incidence of ototoxicity after one course of once-daily IV tobramycin in CF patients. The results showed that cochleotoxic change was highly prevalent, and audiometric measures were more sensitive to ototoxic change than other assessment tools.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Infectious Diseases
Giovanna Batoni, Elisa Catelli, Esinguel Kaya, Arianna Pompilio, Marta Bianchi, Emilia Ghelardi, Giovanni Di Bonaventura, Semih Esin, Giuseppantonio Maisetta
Summary: Therapy of lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients is challenging due to the presence of sticky mucus and antibiotic-tolerant biofilm. This study evaluates the growth of probiotic strains in an artificial sputum medium and their effects on planktonic and biofilm growth of clinical strains of P. aeruginosa. The results show that Lacticaseibacillus rhamnosus and Lactiplantibacillus plantarum can grow in the sputum medium and inhibit the growth of P. aeruginosa, including the pre-formed biofilm.
Article
Immunology
Gretchen E. Bollar, Johnathan D. Keith, Ashley M. Oden, Megan R. Kiedrowski, Susan E. Birket
Summary: This study investigates the impact of small colony variants (SCVs) of Staphylococcus aureus on cystic fibrosis (CF) disease progression. The research shows that SCV infections in CF rats lead to increased weight loss and neutrophilic inflammation compared to normal colony variants (NCVs). Additionally, SCV infections result in a lower macrophage response. These findings suggest that SCV infections directly contribute to lung disease progression in people with CF.
INFECTION AND IMMUNITY
(2022)
Review
Pharmacology & Pharmacy
Nazanin Falconer, Ahmad Abdel-Hafez, Ian A. Scott, Sven Marxen, Stephen Canaris, Michael Barras
Summary: Few studies have examined ML models for UFH dosing, with none ready for clinical routine use. Existing research is hindered by low methodological quality, incomplete reporting of study factors, and lack of external validation and impact analysis.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ranita Kirubakaran, Stefanie Hennig, Ben Maslen, Richard O. Day, Jane E. Carland, Sophie L. Stocker
Summary: This study evaluated the predictive performances of 17 population pharmacokinetic models of tacrolimus in adult heart transplant recipients, showing that these models were unable to adequately describe the pharmacokinetics of tacrolimus in this specific population. Further research is needed to better understand tacrolimus pharmacokinetics in heart transplant recipients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Tjokosela Tikiso, Helen McIlleron, David Burger, Diana Gibb, Helena Rabie, Janice Lee, Marc Lallemant, Mark F. Cotton, Moherndran Archary, Stefanie Hennig, Paolo Denti
Summary: This study investigated the population pharmacokinetics of abacavir in 230 HIV-infected African children, finding that age, concomitant medications, malnutrition, and formulation had influences on abacavir exposure. The results indicated that children on lopinavir/ritonavir or efavirenz had similar abacavir exposures, while concomitant TB treatment and super-boosted lopinavir significantly reduced abacavir concentrations.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Oncology
Rachael Lawson, Lachlan Paterson, Christopher J. Fraser, Stefanie Hennig
Summary: The study aimed to evaluate the ability of model-based personalised dosing tools to estimate busulfan exposure, showing that Bayesian methods demonstrated relatively low bias and precise estimation capabilities. However, there was a trend towards overestimation of exposure compared to clinical practice. Additionally, a reduction in busulfan clearance during treatment was observed.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Centaine L. Snoswell, Keshia R. De Guzman, Michael Barras
Summary: This study investigated the clinical effectiveness of outpatient clinic pharmacists in Australia and found that they are effective at identifying and resolving medication-related problems, with 18% of the resolved recommendations preventing high-risk medication-related harm events.
INTERNAL MEDICINE JOURNAL
(2023)
Correction
Oncology
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kagedal, Angelica L. Quartino, Sandhya Girish, Chunze Li, Whitney P. Kirschbrown
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Emma E. Thomas, Soraia de Camargo Catapan, Helen M. Haydon, Michael Barras, Centaine Snoswell
Summary: During the COVID-19 pandemic, outpatient pharmacy services in Australia quickly adopted telehealth methods, including telephone and video consults. Despite the recommendation to use video consults as the primary mode of contact, pharmacists heavily favored using the telephone. Challenges included additional administrative work, perceptions of patient technology limitations, and preferences for in-person care.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY
(2022)
Review
Geriatrics & Gerontology
Jonathan Yong Jie Lam, Michael Barras, Ian A. Scott, Duncan Long, Leila Shafiee Hanjani, Nazanin Falconer
Summary: This scoping review identified 9 studies evaluating medication harm in frail patients. However, all were limited by the methodological quality and inadequate reporting of study factors. Few high-quality studies described a relationship between medication harm and frailty.
Article
Pharmacology & Pharmacy
Rachael Lawson, Christine E. Staatz, Christopher J. Fraser, Shanti Ramachandran, Lochie Teague, Richard Mitchell, Tracey O'Brien, Stefanie Hennig
Summary: This study characterized the population pharmacokinetics of busulfan and evaluated different methods for measuring its exposure. The results showed that using model-based exposure estimates and dose adjustments improved the proportion of patients achieving the target exposure.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sarah Whatmough, Centaine Snoswell, Gavin Callaghan, Grace Lucas, Michael Barras, Christopher Morris
Summary: This study examined the incidence of infusion reactions after switching patients to a biosimilar brand of infliximab. The results indicate that there is no increased incidence of infusion reactions when using a biosimilar infliximab.
JOURNAL OF PHARMACY PRACTICE AND RESEARCH
(2022)
Correction
Geriatrics & Gerontology
Jonathan Yong Jie Lam, Michael Barras, Ian A. Scott, Duncan Long, Leila Shafiee Hanjani, Nazanin Falconer
Article
Pharmacology & Pharmacy
Ranita Kirubakaran, David W. Uster, Stefanie Hennig, Jane E. Carland, Richard O. Day, Sebastian G. Wicha, Sophie L. Stocker
Summary: A population pharmacokinetic model that considers the tacrolimus-azole antifungal interaction was developed for guiding tacrolimus dosing in heart transplant recipients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Ahmad Abdel-Hafez, Ian A. Scott, Nazanin Falconer, Stephen Canaris, Oscar Bonilla, Sven Marxen, Aaron Van Garderen, Michael Barras
Summary: This study aimed to develop and validate a machine learning algorithm to predict clotting time after administration of unfractionated heparin (UFH). The models were built and tested using data from electronic health records of 5 hospitals, and the results were externally validated. The study demonstrated the accuracy of the developed ML models in predicting and classifying the response to UFH dosing.
INTERACTIVE JOURNAL OF MEDICAL RESEARCH
(2022)
Editorial Material
Pharmacology & Pharmacy
Priya Jayachandran, Rajat Desikan, Sriram Krishnaswami, Stefanie Hennig
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Shannon Finn, Emily D'arcy, Peter Donovan, Shanthi Kanagarajah, Michael Barras
Summary: In a geriatric setting, pharmacist-led partnered discharge prescribing results in significantly less patients with medication errors than the conventional method for both handwritten and digital methods.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2021)